Involvement of PKA, MAPK/ERK and CaMKII, but not PKC in the acute antidepressant-like effect of memantine in mice
Authors:
- Daniela G. SouzaDSDaniela G. Souza
- Rossana C. SolettiRSRossana C. Soletti
- Manuela G. LópezManuela G. López
- Ana Lúcia S. RodriguesAna Lúcia S. Rodrigues
- Nelson H. GabilanNGNelson H. Gabilan
- 1 March 2006
- journal article
- research article
- Published by Elsevier in Neuroscience Letters
- Vol. 395 (2) , 93-97
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Dementia of Alzheimer’s disease and other neurodegenerative disorders—memantine, a new hopePharmacological Research, 2005
- Galantamine and memantine produce different degrees of neuroprotection in rat hippocampal slices subjected to oxygen–glucose deprivationNeuroscience Letters, 2004
- Critical role of brain-derived neurotrophic factor in mood disordersBrain Research Reviews, 2004
- Inhibitory effects of group II mGluR-related drugs on memory performance in micePhysiology & Behavior, 2004
- MAP Kinase Activation by Fluoxetine and Its Relation to Gene Expression in Cultured Rat AstrocytesJournal of Molecular Neuroscience, 2004
- Second Messenger‐Regulated Protein Kinases in the BrainJournal of Neurochemistry, 2000
- Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist—a review of preclinical dataNeuropharmacology, 1999
- Focus on CaMKII: a molecular switch in the pathophysiology and treatment of mood and anxiety disordersInternational Journal of Neuropsychopharmacology, 1999
- Effect of Perinatal Lead Exposure on Rat Behaviour in Open‐Field and Two‐Wky Avoidance TasksBasic & Clinical Pharmacology & Toxicology, 1996
- Is the forced swimming test a suitable model for revealing antidepressant activity?Psychopharmacology, 1988